Mutant Gene Not Sole Explanation For Hiv Non-Progression

September 15, 1997

A recently described genetic mutation does not fully explain why a small proportion of people infected with the human immunodeficiency virus (HIV) remain completely well for a decade or more, according to investigators at the National Institute of Allergy and Infectious Diseases (NIAID).

Instead, the researchers say, the good health of such "long-term nonprogressors" probably is due to multiple factors, which may vary from individual to individual.

Oren Cohen, M.D., a medical officer in NIAID's Laboratory of Immunoregulation (LIR); LIR Lab Chief and NIAID Director Anthony S. Fauci, M.D.; and their colleagues report their findings in the Sept. 15, 1997 issue of The Journal of Clinical Investigation. The study involved 33 patients from LIR's cohort of long-term nonprogressors, the NIAID-supported Multicenter AIDS Cohort Study, and the San Francisco City Clinic Cohort.

"This study fortifies the concept that HIV long-term nonprogressors represent a diverse group," says Dr. Fauci. "Multiple immune system factors, genetic and other host factors, and viral factors contribute to the clinical profiles of these patients, who usually have preserved immune function and low levels of HIV in their bodies."

Recent research has shown that most infecting strains of HIV use a cellular receptor called CCR5, in addition to the CD4 molecule, to enter certain of its target cells. HIV-infected people with a specific mutation in one of their two copies of the gene for this receptor generally have a slower disease course than people with two normal copies of the gene. People with two mutant copies of the CCR5 gene appear -- in most cases -- to be completely protected from HIV infection.

Several epidemiological studies have shown that individuals with one mutant copy of the CCR5 gene are disproportionately represented among long-term nonprogressors. The LIR defines long-term nonprogressors as people who have been HIV-infected for more than seven years, have stable CD4+ T cell counts above 600 per cubic millimeter (mm3) of blood, have no history of HIV-related symptoms, and who have not taken antiretroviral drugs.

Drs. Cohen, Fauci and their team began recruiting long-term nonprogressors five years ago to determine the specific factors that protect these people from HIV disease progression. Soon after the discovery of the role of CCR5 in HIV disease and the association of the mutant CCR5 gene with slower disease progression, the LIR team found that people with one copy of the mutant gene (and one copy of the normal gene) were over-represented in their cohort of long-term nonprogressors.

With that information in hand, they asked the question, do long-term nonprogressors with one copy of the mutant CCR5 gene have less virus in their bodies and higher CD4+ T cell counts compared with long-term nonprogressors with two normal copies of the CCR5 gene -- a situation that would help explain the association of the CCR5 mutation and long-term nonprogression?

The answer, Dr. Cohen says, "was a resounding no." The investigators found that nonprogressors with one copy of the mutant CCR5 gene were indistinguishable from nonprogressors with two normal copies of the gene with regard to all immunologic and virologic parameters they measured, including CD4+ T cell counts and viral load in the bloodstream and lymph nodes.

"Although an HIV-infected individual who carries one copy of the mutant CCR5 gene has an increased chance of becoming a long-term nonprogressor, other factors in the complex interaction between HIV and the body allow individuals with normal copies of the gene to maintain similar immunologic status."

What explains the epidemiological data that show many people with the CCR5 gene mutation in cohorts of long-term nonprogressors?

"Around the time of initial infection with HIV, people with the specific mutation in the CCR5 gene have lower levels of virus in their blood and a smaller initial decline in CD4+ T cells, as compared to other patients," says Dr. Cohen. (See Huang, et al. Nature Medicine 1996;2:1240-1243). "This lower 'set point' probably has an important influence on the subsequent rate of disease progression."

The LIR continues its studies of long-term nonprogressors, and will report important new data from their cohort at the upcoming Interscience Conference on Antimicrobial Agents and Chemotherapy later this month.

"Studies of long-term nonprogressors have contributed greatly to our understanding of the HIV disease process, and provide perhaps the best evidence that protective immunity may exist in HIV infection," says Dr. Fauci. "We owe an enormous debt to the many patients who have come to Bethesda to take part in our studies. The contribution that these individuals have made to science and the fight against AIDS is immeasurable."

Dr. Cohen's and Fauci's collaborators include Mauro Vaccarezza, M.D., Gordon K. Lam, Barbara F. Baird, Kathryn Wildt, Philip M. Murphy, M.D., Ph.D., Peter A. Zimmerman, Ph.D., Thomas B. Nutman, M.D., Cecil H. Fox, Ph.D., Shelley Hoover, Joseph Adelsberger, Michael Baseler, Ph.D., James Arthos, Ph.D., Richard T. Davey, Jr., M.D., Robin L. Dewar, Ph.D., Julia Metcalf, Douglas J. Schwarzentruber, Ph.D., Jan M. Orenstein, M.D., Ph.D., Susan Buchbinder, M.D., Alfred J. Saah, M.D., Roger Detels, M.D., John Phair, M.D., Charles Rinaldo, Ph.D., Joseph B. Margolick, M.D., Ph.D., and Giuseppe Pantaleo, M.D.


Cohen OJ, et al. Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long term non-progressors. Journal of Clinical Investigation 1997;100(7):1581-1589.

NIH/National Institute of Allergy and Infectious Diseases

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to